Takeda Research & Development Fact Sheet

At Takeda, we are a forward-looking, world-class R&D organization that unlocks innovation and delivers transformative
therapies to patients. By focusing R&D efforts on four therapeutic areas and other targeted investments, we push the
boundaries of what is possible in order to bring life-changing therapies to patients worldwide.

Our Focus Areas

ONCOLOGY GASTROENTEROLOGY RARE DISEASES NEUROSCIENCE

We endeavor to deliver
novel medicines to
patients with cancer
worldwide through our
three strategic pillars:
hematologic malignancies,
lung cancer and immuno-
oncology (I/O).
(GI)
We work to restore Life We aspire to transform Our mission is to bring
to Living for patients the treatment of rare innovative medicines to
suffering with GI diseases immunology, rare patients suffering from
across our core disease hematology and lysosomal neurologic and psychiatric
areas: inflammatory bowel storage disorders and diseases for whom
disease, celiac and other expand our focus to bring there are no treatments
luminal gut diseases, transformative or curative available.
motility disorders and therapies to other rare
liver diseases. diseases.

11 9 7 9
clinical-stage assets clinical-stage assets clinical-stage assets clinical-stage assets

A Diverse & Dynamic Pipeline1

40
NEW MOLECULAR ENTITY ~50% PIPELINE WITH ORPHAN
CLINICAL STAGE ASSETS2 DRUG DESIGNATION

MODALITY-DIVERSE PUTTING PATIENTS FIRST EXTERNALLY ORIENTED

RESEARCH PROJECTS
Our Research engine is investing in
next-generation technologies beyond
small molecules to bring a new wave
of innovative treatments to patients.
Small
Takeda's R&D patient access MINDSET
programs, knowledge sharing We seek innovation and partner
and capacity building programs to nurture it, wherever it resides.
have been recognized as Industry We have diverse partnership
Best Practices by the Access to models, each created with aligned
Medicine Foundation. incentives and designed to leverage
what we each do best - together.
R&D ESTABLISHED:
Biologics Since FY16

20+ 50+
Molecules

200+ Active

~70 % Cell & PARTNERSHIPS INITIATIVES

Partnerships
Venture
45+
Gene
Therapies with non-governmental Investment
organizations since 2015 to Financings
support local R&D and healthcare

Peptides & Microbiome

capacity building in underserved
countries and communities. 25+ New Company
Creations
Oligonucleotides & Other Modalities

1 Pipeline as of May 14, 2019

2 Includes assets in our four focus Therapeutic Areas and targeted R&D investments in Plasma-Derived Therapies and Vaccines
© Takeda Pharmaceutical Company Limited. All rights reserved. July 2019.
 Our Global Regional
Footprint Centers*
OSAKA, JAPAN
TOKYO, JAPAN
BOSTON, MA
H R&D Center, Oncology,
GI, Rare Diseases
SHANGHAI, CHINA
SINGAPORE
SAN DIEGO, CA SHONAN, JAPAN
GI, Neuroscience, Neuroscience,
Discovery Technologies Takeda & the ZÜRICH, SWITZERLAND
Center for iPS VIENNA & ORTH, AUSTRIA
Cell Research &
Application, iPark * Each regional center also has a secondary
support team in the general vicinity to
support local regulatory engagement
Employees Worldwide and sustain other R&D activities.

4,400+
LOCAL SITES
Takeda operates in additional countries
for specific R&D functions and/or based
on legal requirements.

R&D Leadership Team

Andy Plump Asit Parikh Emiliangelo Ratti Phil Rowlands Dan Curran Steve Hitchcock
President, Research Head, Head, Neuroscience Head, Oncology Head, Rare Diseases Head, Research
& Development Gastroenterology Therapeutic Area Therapeutic Area Therapeutic Area Unit
Therapeutic Area Unit Unit Unit

Nenad Grmusa Georgia Keresty Wolfram Nothaft Wolfgang Hackel Jeremy Chadwick Anne
Head, Center for R&D Chief Chief Medical Head, Global R&D Head, Regulatory, Heatherington
External Innovation Operating Officer Officer Finance GPSE, Development Head, Data Sciences
Operations & Clinical Institute
Supply Chain

Stefan Wildt Erika Marder Colleen Toshio Fujimoto

Head, Pharmaceutical Head, Global R&D Beauregard General Manager,
Sciences & Translational Human Resources Head, Global R&D Shonan Health
Engine, Cell Therapies Communications Innovation Park (iPark)

© Takeda Pharmaceutical Company Limited. All rights reserved. July 2019.